Functional Roles of Fatty Acids and Their Effects on Human Health

Journal of Parenteral and Enteral Nutrition

Volumn 39, Issue , 2015, Pages 18S-32S

  Calder, Philip C ^a,b,c  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b University Hospital Southampton NHS Foundation Trust   (United Kingdom)

^c KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

fatty acid; fish oil; health; mechanism; monounsaturated; polyunsaturated; saturated; trans; 3

Indexed keywords

CIS FATTY ACID; FATTY ACID; MONOUNSATURATED FATTY ACID; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; SATURATED FATTY ACID; TRANS FATTY ACID; FAT INTAKE;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; ENERGY RESOURCE; GENE CONTROL; GENE EXPRESSION; HEALTH; HUMAN; INFLAMMATORY DISEASE; INTRACELLULAR SIGNALING; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; TISSUE METABOLISM; WELLBEING; ADVERSE EFFECTS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIET; FAT INTAKE; INFLAMMATION; METABOLISM; NEOPLASMS; PHARMACOLOGY; THERAPEUTIC USE;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIET; DIETARY FATS; FATTY ACIDS; HUMANS; INFLAMMATION; NEOPLASMS;

EID: 84939621718     PISSN: 01486071     EISSN: 19412444     Source Type: Journal    
DOI: 10.1177/0148607115595980     Document Type: Review

References (178)

1. Simons K, Gerl MJ., Revitalizing membrane rafts: new tools and insights. Nat Rev Mol Cell Biol. 2010; 11L688-11L699.
2. Johnson DR, Bhatnagar RS, Knoll LJ, Gordon JI., Genetic and biochemical studies of protein N-myristoylation. Annu Rev Biochem. 1994; 63: 869-914.
3. Mitchell DA, Vasudevan A, Linder ME, Deschenes RJ., Protein palmitoylation by a family of DHHC protein S-acyltransferases. J Lipid Res. 2006; 47: 1118-1127.
4. Lin J, Yang R, Tarr PT,. Hyperlipidemic effects of dietary saturated fats mediated through PGC-1beta coactivation of SREBP. Cell. 2005; 120: 261-273.
5. Xu X, So JS, Park JG, Lee AH., Transcriptional control of hepatic lipid metabolism by SREBP and ChREBP. Semin Liver Dis. 2013; 33: 301-311.
6. Strable MS, Ntambi JM., Genetic control of de novo lipogenesis: role in diet-induced obesity. Crit Rev Biochem Mol Biol. 2010; 45: 199-214.
7. Jump DB, Clarke SD., Regulation of gene expression by dietary fat. Annu Rev Nutr. 1999; 19: 63-90.
8. Lee JY, Sohn KH, Rhee SH, Hwang D., Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated through Toll-like receptor 4. J Biol Chem. 2001; 276: 16683-16689.
9. Maloney E, Sweet IR, Hockenbery DM,. Activation of NF-kappaB by palmitate in endothelial cells: a key role for NADPH oxidase-derived superoxide in response to TLR4 activation. Arterioscler Thromb Vasc Biol. 2009; 29: 1370-1375.
10. Wong SW, Kwon MJ, Choi AM, Kim HP, Nakahira K, Hwang DH., Fatty acids modulate Toll-like receptor 4 activation through regulation of receptor dimerization and recruitment into lipid rafts in a reactive oxygen species-dependent manner. J Biol Chem. 2009; 284: 27384-27392.
11. Erridge C, Samani NJ., Saturated fatty acids do not directly stimulate Toll-like receptor signaling. Arterioscler Thromb Vasc Biol. 2009; 29: 1944-1949.
12. Eguchi K, Manabe I, Oishi-Tanaka Y,. Saturated fatty acid and TLR signaling link β cell dysfunction and islet inflammation. Cell Metab. 2012; 15: 518-533.
13. Mensink RP, Katan MB., Effect of dietary fatty acids on serum lipids and lipoproteins: a meta-analysis of 27 trials. Arterioscler Thromb. 1992; 12: 911-919.
14. Mensink RP, Zock PL, Kester AD, Katan MB,. Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. Am J Clin Nutr. 20 03; 77: 1146-1155.
15. Risérus U., Fatty acids and insulin sensitivity. Curr Opin Clin Nutr Metab Care. 2008; 11: 100-105.
16. Vessby B, Uusitupa M, Hermansen K, KANWU Study. Substituting dietary saturated for monounsaturated fat impairs insulin sensitivity in healthy men and women: the KANWU Study. Diabetologia. 2001; 44: 312-319.
17. Jebb SA, Lovegrove JA, Griffin BA, RISCK Study Group. Effect of changing the amount and type of fat and carbohydrate on insulin sensitivity and cardiovascular risk: the RISCK (Reading, Imperial, Surrey, Cambridge, and Kings) trial. Am J Clin Nutr. 2010; 92: 748-758.
18. Tierney AC, McMonagle J, Shaw DI,. Effects of dietary fat modification on insulin sensitivity and on other risk factors of the metabolic syndrome-LIPGENE: a European randomized dietary intervention study. Int J Obes (Lond). 2011; 35: 800-809.
19. Forouhi NG, Koulman A, Sharp SJ,. Differences in the prospective association between individual plasma phospholipid saturated fatty acids and incident type 2 diabetes: the EPIC-InterAct case-cohort study. Lancet Diabetes Endocrinol. 2014; 2: 810-818.
20. Fernández-Real JM, Broch M, Vendrell J, Ricart W., Insulin resistance, inflammation, and serum fatty acid composition. Diabetes Care. 2003; 26: 1362-1368.
21. Klein-Platat C1, Drai J, Oujaa M, Schlienger JL, Simon C,. Plasma fatty acid composition is associated with the metabolic syndrome and low-grade inflammation in overweight adolescents. Am J Clin Nutr. 2005; 82: 1178-1184.
22. Baer DJ, Judd JT, Clevidence BA, Tracy RP., Dietary fatty acids affect plasma markers of inflammation in healthy men fed controlled diets: a randomized crossover study. Am J Clin Nutr. 2004; 79: 969-973.
23. Khaw KT, Friesen MD, Riboli E, Luben R, Wareham N., Plasma phospholipid fatty acid concentration and incident coronary heart disease in men and women: the EPIC-Norfolk prospective study. PLoS Med. 2012; 9: e1001255.
24. Siri-Tarino PW, Sun Q, Hu FB, Krauss RM., Meta-analysis of prospective cohort studies evaluating the association of saturated fat with cardiovascular disease. Am J Clin Nutr. 2010; 91: 535-546.
25. Chowdhury R, Warnakula S, Kunutsor S,. Association of dietary, circulating, and supplement fatty acids with coronary risk: a systematic review and meta-analysis. Ann Intern Med. 2014; 160: 398-406.
26. Jakobsen MU, OReilly EJ, Heitmann BL,. Major types of dietary fat and risk of coronary heart disease: a pooled analysis of 11 cohort studies. Am J Clin Nutr. 2009; 89: 1425-1432.
27. Bonanome A, Pagnan A, Biffanti S,. Effect of dietary monounsaturated and polyunsaturated fatty acids on the susceptibility of plasma low density lipoproteins to oxidative modification. Arterioscler Thromb. 1992; 12: 529-533.
28. Yaqoob P., Monounsaturated fatty acids and immune function. Eur J Clin Nutr. 2002; 56 (suppl 3): S9-S13.
29. Bermudez B, Lopez S, Ortega A,. Oleic acid in olive oil: from a metabolic framework toward a clinical perspective. Curr Pharm Des. 2011; 17: 831-843.
30. Pérez-Martínez P, García-Ríos A, Delgado-Lista J, Pérez-Jiménez F, López-Miranda J., Mediterranean diet rich in olive oil and obesity, metabolic syndrome and diabetes mellitus. Curr Pharm Des. 2011; 17: 769-777.
31. van Deursen D, van Leeuwen M, Akdogan D, Adams H, Jansen H, Verhoeven AJ,. Activation of hepatic lipase expression by oleic acid: possible involvement of USF1. Nutrients. 2009; 1: 133-147.
32. Schwingshackl L, Hoffmann G., Monounsaturated fatty acids, olive oil and health status: a systematic review and meta-analysis of cohort studies. Lipids Health Dis. 2014; 13: 154.
33. Estruch R, Ros E, Salas-Salvadó J, PREDIMED Study Investigators. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med. 2013; 368: 1279-1290.
34. Cao H, Gerhold K, Mayers JR, Wiest MM, Watkins SM, Hotamisligil GS., Identification of a lipokine, a lipid hormone linking adipose tissue to systemic metabolism. Cell. 2008; 134: 933-944.
35. Guo X, Li H, Xu H,. Palmitoleate induces hepatic steatosis but suppresses liver inflammatory response in mice. PLoS One. 2012; 7: e39286.
36. Curb JD, Wergowske G, Dobbs JC, Abbott RD, Huang B., Serum lipid effects of a high-monounsaturated fat diet based on macadamia nuts. Arch Intern Med. 2000; 160: 1154-1158.
37. Garg ML, Blake RJ, Wills RB., Macadamia nut consumption lowers plasma total and LDL cholesterol levels in hypercholesterolemic men. J Nutr. 2003; 133: 1060-1063.
38. Stefan N, Kantartzis K, Celebi N,. Circulating palmitoleate strongly and independently predicts insulin sensitivity in humans. Diabetes Care. 2010; 33: 405-407.
39. Wang L, Folsom AR, Zheng ZJ, Pankow JS, Eckfeldt JH, ARIC Study Investigators. Plasma fatty acid composition and incidence of diabetes in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Clin Nutr. 2003; 78: 91-98.
40. Blasbalg TL, Hibbeln JR, Ramsden CE, Majchrzak SF, Rawlings RR., Changes in consumption of omega-3 and omega-6 fatty acids in the United States during the 20th century. Am J Clin Nutr. 2011; 93: 950-962.
41. Rabionet M, Gorgas K, Sandhoff R., Ceramide synthesis in the epidermis. Biochim Biophys Acta. 2014; 1841: 422-434.
42. Cho BH, Dokko RC, Chung BH., Oleic, linoleic and linolenic acids enhance receptor-mediated uptake of low density lipoproteins in Hep-G2 cells. J Nutr Biochem. 2002; 13: 330-336.
43. Sato M, Yoshida S, Nagao K, Imaizumi K., Superiority of dietary safflower oil over olive oil in lowering serum cholesterol and increasing hepatic mRNAs for the LDL receptor and cholesterol 7alpha-hydroxylase in exogenously hypercholesterolemic (exHC) rats. Biosci Biotechnol Biochem. 2000; 64: 1111-1117.
44. Wang T, Yu WG, Powell WS., Formation of monohydroxy derivatives of arachidonic acid, linoleic acid, and oleic acid during oxidation of low density lipoprotein by copper ions and endothelial cells. J Lipid Res. 1992; 33: 525-537.
45. Czernichow S1, Thomas D, Bruckert E,. n-6 Fatty acids and cardiovascular health: a review of the evidence for dietary intake recommendations. Br J Nutr. 2010; 104: 788-796.
46. Risérus U, Willett WC, Hu FB., Dietary fats and prevention of type 2 diabetes. Prog Lipid Res. 2009; 48: 44-51.
47. Vangaveti V, Baune BT, Kennedy RL., Hydroxyoctadecadienoic acids: novel regulators of macrophage differentiation and atherogenesis. Ther Adv Endocrinol Metab. 2010; 1: 51-60.
48. Hennig B1, Toborek M, Joshi-Barve S,. Linoleic acid activates nuclear transcription factor-kappa B (NF-kappa B) and induces NF-kappa B-dependent transcription in cultured endothelial cells. Am J Clin Nutr. 1996; 63: 322-328.
49. Pischon T, Hankinson SE, Hotamisligil GS, Rifai N, Willett WC, Rimm EB., Habitual dietary intake of n-3 and n-6 fatty acids in relation to inflammatory markers among US men and women. Circulation. 2003; 108: 155-160.
50. Petersson H, Basu S, Cederholm T, Risérus U., Serum fatty acid composition and indices of stearoyl-CoA desaturase activity are associated with systemic inflammation: longitudinal analyses in middle-aged men. Br J Nutr. 2008; 99: 1186-1189.
51. Ramsden CE, Hibbeln JR, Majchrzak SF, Davis JM., n-6 Fatty acid-specific and mixed polyunsaturate dietary interventions have different effects on CHD risk: a meta-analysis of randomised controlled trials. Br J Nutr. 2010; 104: 1586-1600.
52. Mozaffarian D, Micha R, Wallace S., Effects on coronary heart disease of increasing polyunsaturated fat in place of saturated fat: a systematic review and meta-analysis of randomized controlled trials. PLoS Med. 2010; 7: e1000252.
53. Camandola S, Leonarduzzi G, Musso T,. Nuclear factor kB is activated by arachidonic acid but not by eicosapentaenoic acid. Biochem Biophys Res Commun. 1996; 229: 643-647.
54. Turcotte C, Chouinard F, Lefebvre JS, Flamand N., Regulation of inflammation by cannabinoids, the endocannabinoids 2-arachidonoyl-glycerol and arachidonoyl-ethanolamide, and their metabolites. J Leukoc Biol. 2015; 97 (6): 1049-1070.
55. Calder PC., Marine omega-3 fatty acids and inflammatory processes: effects, mechanisms and clinical relevance. Biochim Biophys Acta. 2015; 1851: 469-484.
56. Vachier I, Chanez P, Bonnans C, Godard P, Bousquet J, Chavis C., Endogenous anti-inflammatory mediators from arachidonate in human neutrophils. Biochem Biophys Res Commun. 2002; 290: 219-224.
57. Yaqoob P, Pala HS, Cortina-Borja M, Newsholme EA, Calder PC., Encapsulated fish oil enriched in alpha-tocopherol alters plasma phospholipid and mononuclear cell fatty acid compositions but not mononuclear cell functions. Eur J Clin Invest. 2000; 30: 260-274.
58. Thies F, Nebe-von-Caron G, Powell JR, Yaqoob P, Newsholme EA, Calder PC., Dietary supplementation with gamma-linolenic acid or fish oil decreases T lymphocyte proliferation in healthy older humans. J Nutr. 2001; 131: 1918-1927.
59. Yli-Jama P, Seljeflot I, Meyer HE, Hjerkinn EM, Arnesen H, Pedersen JI., Serum non-esterified very long-chain PUFA are associated with markers of endothelial dysfunction. Atherosclerosis. 2002; 164: 275-281.
60. Ferrucci L, Cherubini A, Bandinelli S,. Relationship of plasma polyunsaturated fatty acids to circulating inflammatory markers. J Clin Endocrinol Metab. 2006; 91: 439-446.
61. Skinner ER, Watt C, Besson JA, Best PV., Differences in the fatty acid composition of the grey and white matter of different regions of the brains of patients with Alzheimers disease and control subjects. Brain. 1993; 116: 717-725.
62. Makrides M, Neumann MA, Byard RW, Simmer K, Gibson RA., Fatty acid composition of brain, retina, and erythrocytes in breast- and formula-fed infants. Am J Clin Nutr. 1994; 60: 189-194.
63. Crawford MA, Casperd NM, Sinclair AJ., The long chain metabolites of linoleic and linolenic acids in liver and brain in herbivores and carnivores. Comp Biochem Physiol. 1976; 54B: 395-401.
64. Calder PC., Very long chain omega-3 (n-3) fatty acids and human health. Eur J Lipid Sci Technol. 2014; 116: 1280-1300.
65. Niu SL, Mitchell DC, Lim SY,. Reduced G protein-coupled signaling efficiency in retinal rod outer segments in response to n-3 fatty acid deficiency. J Biol Chem. 2004; 279: 31098-31104.
66. Calder PC., Mechanisms of action of (n-3) fatty acids. J Nutr. 2012; 142: 592S-599S.
67. Novak TE, Babcock TA, Jho DH, Helton WS, Espat NJ., NF-kappa B inhibition by omega-3 fatty acids modulates LPS-stimulated macrophage TNF-alpha transcription. Am J Physiol. 2003; 284: L84-L89.
68. Gottlicher M, Widmaek E, Li Q, Gustafsson J-A., Fatty acids activate a chimera of the clofibric acid-activated receptor and the glucocorticoid receptor. Proc Natl Acad Sci USA. 1992; 89: 4653-4657.
69. Krey G, Braissant O, LHorset F,. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol Endocrinol. 1997; 11: 779-791.
70. Clarke SD., The multi-dimensional regulation of gene expression by fatty acids: polyunsaturated fats as nutrient sensors. Curr Opin Lipidol. 2004; 15: 13-18.
71. Lapillonne A, Clarke SD, Heird WC., Polyunsaturated fatty acids and gene expression. Curr Opin Clin Nutr Metab Care. 2004; 7: 151-156.
72. Jump DB., Dietary polyunsaturated fatty acids and regulation of gene transcription. Curr Opin Lipidol. 2002; 13: 155-164.
73. Jump DB., n-3 Polyunsaturated fatty acid regulation of hepatic gene transcription. Curr Opin Lipidol. 2008; 19: 242-247.
74. Deckelbaum RJ, Worgall TS, Seo T., n-3 Fatty acids and gene expression. Am J Clin Nutr. 2006; 83: 1520S-1525S.
75. Oh DY, Talukdar S, Bae EJ,. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell. 2010; 142: 687-698.
76. Stevens L, Zhang W, Peck L,. EFA supplementation in children with inattention, hyperactivity, and other disruptive behaviors. Lipids. 2003; 38: 1007-1021.
77. Richardson AJ, Puri BK., A randomized double-blind, placebo-controlled study of the effects of supplementation with highly unsaturated fatty acids on ADHD-related symptoms in children with specific learning difficulties. Prog Neuropsychopharmacol Biol Psych. 2002; 26: 233-239.
78. Yui K, Koshiba M, Nakamura S, Kobayashi Y., Effects of large doses of arachidonic acid added to docosahexaenoic acid on social impairment in individuals with autism spectrum disorders: a double-blind, placebo-controlled, randomized trial. J Clin Psychopharmacol. 2012; 32: 200-206.
79. Meguid NA, Atta HM, Gouda AS, Khalil RO., Role of polyunsaturated fatty acids in the management of Egyptian children with autism. Clin Biochem. 2008; 41: 1044-1048.
80. Perera H, Jeewandara KC, Seneviratne S, Guruge C., Combined ‰3 and ‰6 supplementation in children with attention-deficit hyperactivity disorder (ADHD) refractory to methylphenidate treatment: a double-blind, placebo-controlled study. J Child Neurol. 2012; 27: 747-753.
81. Milte CM, Parletta N, Buckley JD, Coates AM, Young RM, Howe PR., Eicosapentaenoic and docosahexaenoic acids, cognition, and behavior in children with attention-deficit/hyperactivity disorder: a randomized controlled trial. Nutrition. 2012; 28: 670-677.
82. Gustafsson PA, Birberg-Thornberg U, Duchén K,. EPA supplementation improves teacher-rated behaviour and oppositional symptoms in children with ADHD. Acta Paediatr. 2010; 99: 1540-1549.
83. Bélanger SA, Vanasse M, Spahis S,. Omega-3 fatty acid treatment of children with attention-deficit hyperactivity disorder: a randomized, double-blind, placebo-controlled study. Paediatr Child Health. 2009; 14: 89-98.
84. Sorgi PJ, Hallowell EM, Hutchins HL, Sears B., Effects of an open-label pilot study with high-dose EPA/DHA concentrates on plasma phospholipids and behavior in children with attention deficit hyperactivity disorder. Nutr J. 2007; 6: 16.
85. Su KP, Huang SY, Chiu CC, Shen WW., Omega-3 fatty acids in major depressive disorder: a preliminary double-blind, placebo-controlled trial. Eur Neuropsychopharmacol. 2003; 13: 267-271.
86. Stoll AL, Severus WE, Freeman MP,. Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Arch Gen Psychiatry. 1999; 56: 407-412.
87. Nemets B, Stahl Z, Belmaker RH., Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. Am J Psychiatry. 2002; 159: 477-479.
88. Peet M, Brind J, Ramchand CN, Shah S, Vankar GK., Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Schizophr Res. 2001; 49: 243-251.
89. Peet M, Horrobin DF., A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch Gen Psychiatry. 2002; 59: 913-919.
90. Fenton WS, Dickerson F, Boronow J, Hibbeln JR, Knable M., A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. Am J Psychiatry. 2001; 158: 2071-2074.
91. Hamazaki T, Sawazaki S, Itomura M,. The effect of docosahexaenoic acid on aggression in young adults: a placebo-controlled double-blind study. J Clin Invest. 1996; 97: 1129-1133.
92. Hamazaki T, Thienprasert A, Kheovichai K, Samuhaseneetoo S, Nagasawa T, Watanabe S., The effect of docosahexaenoic acid on aggression in elderly Thai subjects-a placebo-controlled double-blind study. Nutr Neurosci. 2002; 5: 37-41.
93. Shearer GC, Savinova OV, Harris WS., Fish oil-how does it reduce plasma triglycerides? Biochim Biophys Acta. 2012; 1821: 843-851.
94. Harris WS., n-3 Fatty acids and lipoproteins: comparison of results from human and animal studies. Lipids. 1996; 31: 243-252.
95. Harris WS., n-3 Fatty acids and serum lipoproteins: human studies. Am J Clin Nutr. 1997; 65 (5)(suppl): 1645S-1654S.
96. Balk EM, Lichtenstein AH, Chung M, Kupelnick B, Chew P, Lau J., Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review. Atherosclerosis. 2006; 189: 19-30.
97. Mori TA, Burke V, Puddey IB,. Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men. Am J Clin Nutr. 2000; 71: 1085-1094.
98. Woodman RJ, Mori TA, Burke V, Puddey IB, Watts GF, Beilin LJ., Effects of purified eicosapentaenoic and docosahexaenoic acids on glycemic control, blood pressure, and serum lipids in type 2 diabetic patients with treated hypertension. Am J Clin Nutr. 2002; 76: 1007-1015.
99. Suzukawa M, Abbey M, Howe PR, Nestel PJ., Effects of fish oil fatty acids on low density lipoprotein size, oxidizability, and uptake by macrophages. J Lipid Res. 1995; 36: 473-484.
100. Woodman RJ, Mori TA, Burke V,. Docosahexaenoic acid but not eicosapentaenoic acid increases LDL particle size in treated hypertensive type 2 diabetic patients. Diabetes Care. 2003; 26: 253.
101. Neff LM, Culiner J, Cunningham-Rundles S,. Algal docosahexaenoic acid affects plasma lipoprotein particle size distribution in overweight and obese adults. J Nutr. 2011; 141: 207-213.
102. Appel LJ, Miller ER III, Seidler AJ, Whelton PK., Does supplementation of diet with €fish oil reduce blood pressure? A meta-analysis of controlled clinical trials. Arch Intern Med. 1993; 153: 1429-1438.
103. Morris MC, Sacks F, Rosner B., Does fish oil lower blood pressure? A meta-analysis of controlled trials. Circulation. 1993; 88: 523-533.
104. Geleijnse JM, Giltay EJ, Grobbee DE, Donders AR, Kok FJ., Blood pressure response to fish oil supplementation: metaregression analysis of randomized trials. J Hypertension. 2002; 20: 1493-1499.
105. Balk E, Chung M, Lichtenstein A., Effects of omega-3 fatty acids on cardiovascular risk factors and intermediate markers of cardiovascular disease. Evid Rep Technol Assess (Summ). 2004; 93: 1-6.
106. Hartweg J, Farmer AJ, Holman RR, Neil HA., Meta-analysis of the effects of n-3 polyunsaturated fatty acids on haematological and thrombogenic factors in type 2 diabetes. Diabetologia. 2007; 50: 250-258.
107. Miller PE, Van Elswyk M, Alexander DD., Long-chain omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and blood pressure: a meta-analysis of randomized controlled trials. Am J Hypertens. 2014; 27: 885-896.
108. Calder PC, Ahluwalia N, Brouns F,. Dietary factors and low-grade inflammation in relation to overweight and obesity. Br J Nutr. 2011; 106 (suppl 3): S5-S78.
109. Itariu BK, Zeyda M, Hochbrugger EE,. Long-chain n-3 PUFAs reduce adipose tissue and systemic inflammation in severely obese nondiabetic patients: a randomized controlled trial. Am J Clin Nutr. 2012; 96: 1137-1149.
110. Spencer M, Finlin BS, Unal R,. Omega-3 fatty acids reduce adipose tissue macrophages in human subjects with insulin resistance. Diabetes. 2013; 62 (5): 1709-1717.
111. Miles EA, Calder PC., Influence of marine n-3 polyunsaturated fatty acids on immune function and a systematic review of their effects on clinical outcomes in rheumatoid arthritis. Br J Nutr. 2012; 107 (suppl 2): S171-S184.
112. Miles EA, Calder PC., Omega-6 and omega-3 polyunsaturated fatty acids and allergic diseases in infancy and childhood. Curr Pharm Des. 2014; 20: 946-953.
113. Thienprasert A1, Samuhaseneetoo S, Popplestone K, West AL, Miles EA, Calder PC,. Fish oil n-3 polyunsaturated fatty acids selectively affect plasma cytokines and decrease illness in Thai schoolchildren: a randomized, double-blind, placebo-controlled intervention trial. J Pediatr. 2009; 154: 391-395.
114. Malan L, Baumgartner J, Calder PC, Zimmermann MB, Smuts CM., n-3 Long-chain PUFAs reduce respiratory morbidity caused by iron supplementation in iron-deficient South African schoolchildren: a randomized, double-blind, placebo-controlled intervention. Am J Clin Nutr. 2015; 101 (3): 668-679.
115. Kris-Etherton PM, Harris WS, Appel LJ., Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. American Heart Association Nutrition Committee. Circulation. 2002; 106: 2747-2757.
116. London B, Albert C, Anderson M,. Omega-3 fatty acids and cardiac arrhythmias: prior studies and recommendations for future research: a report from the National Heart, Lung, and Blood Institute and Office of Dietary Supplements Omega-3 Fatty Acids and Their Role in Cardiac Arrhythmogenesis Workshop. Circulation. 2007; 116: e320-e335.
117. Wang C, Harris WS, Chung M,. n-3 Fatty acids from fish or fish-oil supplements, but not alpha-linolenic acid, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies: a systematic review. Am J Clin Nutr. 2006; 84: 5-17.
118. Calder PC., n-3 Fatty acids and cardiovascular disease: evidence explained and mechanisms explored. Clin Sci. 2004; 107: 1-11.
119. Saravanan P, Davidson NC, Schmidt EB, Calder PC., Cardiovascular effects of marine omega-3 fatty acids. Lancet. 2010; 376: 540-550.
120. De Caterina R,. n-3 Fatty acids in cardiovascular disease. N Engl J Med. 2011; 364: 2439-2450.
121. Burr ML, Fehily AM, Gilbert JF,. Effects of changes in fat, fish and fibre intake on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet. 1989;ii: 757-761.
122. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet. 1999; 354: 447-455.
123. Marchioli R, Barzi F, Bomba E, GISSI-Prevenzione Investigators. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction-time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nellInfarto Miocardico (GISSI)-Prevenzione. Circulation. 2002; 105: 1897-1903.
124. Yokoyama M, Origasa H, Matsuzaki M, Japan EPA Lipid Intervention Study (JELIS) Investigators. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007; 369: 1090-1098.
125. Gissi-HF Investigators, Tavazzi L, Maggioni AP,. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008; 372: 1223-1230.
126. Bucher HC, Hengstler P, Schindler C, Meier G., n-3 Polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med. 2002; 112: 298-304.
127. Studer M, Briel M, Leimenstoll B, Glass TR, Bucher HC., Effect of different antilipidemic agents and diets on mortality: a systematic review. Arch Intern Med. 2005; 165: 725-730.
128. Leon H, Shibata MC, Sivakumaran S, Dorgan M, Chatterley T, Tsuyuki RT., Effect of fish oil on arrhythmias and mortality: systematic review. BMJ. 2009; 338: a2931.
129. Galan P, Kesse-Guyot E, Czernichow S, Briancon S, Blacher J, Hercberg S, SU.FOL. OM3 Collaborative Group. Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. BMJ. 2010; 341: c6273.
130. Kromhout D, Giltay EJ, Geleijnse JM, Alpha Omega Trial Group. n-3 Fatty acids and cardiovascular events after myocardial infarction. N Engl J Med. 2010; 363: 2015-2026.
131. Rauch B, Schiele R, Schneider S, OMEGA Study Group. OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation. 2010: 122; 2152-2159.
132. Risk and Prevention Study Collaborative Group, Roncaglioni MC, Tombesi M,. n-3 Fatty acids in patients with multiple cardiovascular risk factors. N Engl J Med. 2013; 368: 1800-1808.
133. Bosch J, Gerstein HC, Dagenais GR, ORIGIN Trial Investigators. n-3 Fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med. 2012; 367: 309-318.
134. Kwak SM, Myung SK, Lee YJ, Seo HG, Korean Meta-analysis Study Group. Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease: a meta-analysis of randomized, double-blind, placebo-controlled trials. Arch Intern Med. 2012; 172: 686-694.
135. Kotwal S, Jun M, Sullivan D, Perkovic V, Neal B., Omega 3 fatty acids and cardiovascular outcomes: systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes. 2012; 5: 808-818.
136. Rizos EC, Ntzani EE, Bika E, Kostapanos MS, Elisaf MS., Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA. 2012; 308: 1024-1033.
137. Casula M, Soranna D, Catapano AL, Carrao G., Long-term effect of high dose omega-3 fatty acid supplementation for secondary prevention of cardiovascular outcomes: a meta-analysis of randomized, double blind, placebo controlled trials. Atheroscler Suppl. 2013; 14: 243-251.
138. Wen YT, Dai JH, Gao Q., Effects of omega-3 fatty acid on major cardiovascular events and mortality in patients with coronary heart disease: a meta-analysis of randomized controlled trials. Nutr Metab Cardiovasc Dis. 2014; 24: 470-475.
139. Harris WS, Miller M, Tighe AP, Davidson MH, Schaefer EJ., Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives. Atherosclerosis. 2008; 197: 12-24.
140. Xin W, Wei W, Li XY., Short-term effects of fish-oil supplementation on heart rate variability in humans: a meta-analysis of randomized controlled trials. Am J Clin Nutr. 2013; 97: 926-935.
141. Leaf A, Xiao YF., The modulation of ionic currents in excitable tissues by n-3 polyunsaturated fatty acids. J Memb Biol. 2001; 184: 263-271.
142. von Schacky C, Fischer S, Weber PC,. Long term effects of dietary marine ‰-3 fatty acids upon plasma and cellular lipids, platelet function, and eicosanoid formation in humans. J Clin Invest. 1985; 76: 1626-1631.
143. Thies F, Rerkasem K, Williams J,. Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial. Lancet. 2003; 361: 477-485.
144. Cawood AL, Ding R, Napper FL,. Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability. Atherosclerosis. 2010; 212: 252-259.
145. Gleissman H, Johnsen JI, Kogner P., Omega-3 fatty acids in cancer, the protectors of good and the killers of evil? Exp Cell Res. 2010; 316: 1365-1373.
146. Merendino N, Costantini L, Manzi L, Molinari R, DEliseo D, Velotti F., Dietary ‰-3 polyunsaturated fatty acids DHA: a potential adjuvant in the treatment of cancer. BioMed Res Int. 2013; 2013: 310186.
147. Wang D, Dubois RN., Eicosanoids and cancer. Nat Rev Cancer. 2010; 10: 181-193.
148. Vaughan VC, Hassing MR, Lewandowski PA., Marine polyunsaturated fatty acids and cancer therapy. Br J Cancer. 2013; 108: 486-492.
149. Gerber M., Omega-3 fatty acids and cancers: a systematic update review of epidemiological studies. Br J Nutr. 2012; 107 (suppl 2): S2228-S2239.
150. Makarem N, Chandran U, Bandera EV, Parekh N., Dietary fat in breast cancer survival. Annu Rev Nutr. 2013; 33: 319-348.
151. Elia M, Van Bokhorst-de van der Schueren MA, Garvey J,. Enteral (oral or tube administration) nutritional support and eicosapentaenoic acid in patients with cancer: a systematic review. Int J Oncol. 2006; 28: 5-23.
152. Alfano CM, Imayama I, Neuhouser ML,. Fatigue, inflammation, and ‰-3 and ‰-6 fatty acid intake among breast cancer survivors. J Clin Oncol. 2012; 30: 1280-1287.
153. Cerchietti LC, Navigante AH, Castro MA., Effects of eicosapentaenoic and docosahexaenoic n-3 fatty acids from fish oil and preferential Cox-2 inhibition on systemic syndromes in patients with advanced lung cancer. Nutr Cancer. 2007; 59: 14-20.
154. van der Meij BS, Langius JA, Spreeuwenberg MD,. Oral nutritional supplements containing n-3 polyunsaturated fatty acids affect quality of life and functional status in lung cancer patients during multimodality treatment: an RCT. Eur J Clin Nutr. 2012; 66: 399-404.
155. Sala-Vila A, Folkes J, Calder PC., The effect of three lipid emulsions differing in fatty acid composition on growth, apoptosis and cell cycle arrest in the HT-29 colorectal cancer cell line. Clin Nutr. 2010; 29: 519-524.
156. Murphy RA, Mourtzakis M, Chu QS, Baracos VE, Reiman T, Mazurak VC., Supplementation with fish oil increases first-line chemotherapy efficacy in patients with advanced nonsmall cell lung cancer. Cancer. 2011; 117: 3774-3780.
157. Roodhart JM, Daenen LG, Stigter EC,. Mesenchymal stem cells induce resistance to chemotherapy through the release of platinum-induced fatty acids. Cancer Cell. 2011; 20: 370-383.
158. Daenen LGM, Cirkel GA, Houthuijzen JM,. Increased plasma levels of chemoresistance-inducing fatty acid 16:4(n-3) after consumption of fish and fish oil. JAMA Oncol. 2015; 1 (3): 350-358.
159. Weed HG, Ferguson ML, Gaff RL, Hustead DS, Nelson JL, Voss AC., Lean body mass gain in patients with head and neck squamous cell cancer treated perioperatively with a protein- and energy-dense nutritional supplement containing eicosapentaenoic acid. Head Neck. 2011; 33: 1027-1033.
160. Murphy RA, Mourtzakis M, Chu QS, Baracos VE, Reiman T, Mazurak VC., Nutritional intervention with fish oil provides a benefit over standard of care for weight and skeletal muscle mass in patients with nonsmall cell lung cancer receiving chemotherapy. Cancer. 2011; 117: 1775-1782.
161. Fearon KC, Barber MD, Moses AG,. Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia. J Clin Oncol. 2006; 24: 3401-3407.
162. Guarcello M, Riso S, Buosi R, dAndrea F., EPA-enriched oral nutritional support in patients with lung cancer: effects on nutritional status and quality of life. Nutr Ther Metab. 2007; 25: 25-30.
163. Burdge GC, Calder PC., Dietary alpha-linolenic acid and health-related outcomes: a metabolic perspective. Nutr Res Rev. 2006; 19: 26-52.
164. Chan JK, McDonald BE, Gerrard JM, Bruce VM, Weaver BJ, Holub BJ., Effect of dietary alpha-linolenic acid and its ratio to linoleic acid on platelet and plasma fatty acids and thrombogenesis. Lipids. 1993; 28: 811-817.
165. Goyens PL, Spilker ME, Zock PL, Katan MB, Mensink RP., Conversion of alpha-linolenic acid in humans is influenced by the absolute amounts of alpha-linolenic acid and linoleic acid in the diet and not by their ratio. Am J Clin Nutr. 2006; 84: 44-53.
166. Finnegan YE, Minihane AM, Leigh-Firbank EC,. Plant- and marine-derived n-3 polyunsaturated fatty acids have differential effects on fasting and postprandial blood lipid concentrations and on the susceptibility of LDL to oxidative modification in moderately hyperlipidemic subjects. Am J Clin Nutr. 2003; 77: 783-795.
167. Arterburn LM, Hall EB, Oken H., Distribution, interconversion, and dose response of n-3 fatty acids in humans. Am J Clin Nutr. 2006; 83 (6)(suppl): 1467S-1476S.
168. Egert S, Kannenberg F, Somoza V, Erbersdobler HF, Wahrburg U., Dietary alpha-linolenic acid, EPA, and DHA have differential effects on LDL fatty acid composition but similar effects on serum lipid profiles in normolipidemic humans. J Nutr. 2009; 139: 861-868.
169. Zhao G, Etherton TD, Martin KR, West SG, Gillies PJ, Kris-Etherton PM., Dietary alpha-linolenic acid reduces inflammatory and lipid cardiovascular risk factors in hypercholesterolemic men and women. J Nutr. 2004; 134: 2991-2997.
170. Caughey GE, Mantzioris E, Gibson RA, Cleland LG, James MJ., The effect on human tumor necrosis factor alpha and interleukin 1 beta production of diets enriched in n-3 fatty acids from vegetable oil or fish oil. Am J Clin Nutr. 1996; 63: 116-122.
171. Pan A, Chen M, Chowdhury R,. α-Linolenic acid and risk of cardiovascular disease: a systematic review and meta-analysis. Am J Clin Nutr. 2012; 96: 1262-1273.
172. Kaur G, Cameron-Smith D, Garg M, Sinclair AJ., Docosapentaenoic acid (22:5n-3): a review of its biological effects. Prog Lipid Res. 2011; 50: 28-34.
173. Zock PL, Katan MB, Mensink RP., Dietary trans fatty acids and lipoprotein cholesterol. Am J Clin Nutr. 1995; 61: 617.
174. Gayet-Boyer C, Tenenhaus-Aziza F, Prunet C,. Is there a linear relationship between the dose of ruminant trans-fatty acids and cardiovascular risk markers in healthy subjects: results from a systematic review and meta-regression of randomised clinical trials. Br J Nutr. 2014; 112: 1914-1922.
175. Tricon S, Burdge GC, Kew S,. Opposing effects of cis-9,trans-11 and trans-10,cis-12 conjugated linoleic acid on blood lipids in healthy humans. Am J Clin Nutr. 2004; 80: 614-620.
176. Lopez-Garcia E, Schulze MB, Meigs JB,. Consumption of trans fatty acids is related to plasma biomarkers of inflammation and endothelial dysfunction. J Nutr. 2005; 135: 562-566.
177. Willett WC, Stampfer MJ, Manson JE,. Intake of trans fatty acids and risk of coronary heart disease among women. Lancet. 1993; 341 (8845): 581-585.
178. Wang Q, Imamura F, Lemaitre RN,. Plasma phospholipid trans-fatty acids levels, cardiovascular diseases, and total mortality: the cardiovascular health study. J Am Heart Assoc. 2014; 3: e000914.